Current Diabetes Reports

, Volume 3, Issue 4, pp 293–298 | Cite as

Adipokines, inflammation, and the endothelium in diabetes

  • Waleed Aldhahi
  • Osama Hamdy


Cytokines are biologically active low molecular weight proteins that possess several endocrine and metabolic functions and are known products of the immune system and inflammation. Several of these cytokines were shown to be independent risk factors for cerebrovascular and coronary artery disease. Because visceral and subcutaneous adipose tissues are the major sources of cytokines (adipokines), increased adipose tissue mass is associated with alteration in adipokine production (eg, overexpression of tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], plasminogen activator inhibitor-1 [PAI-1], and underexpression of adiponectin in adipose tissue). The proinflammatory status associated with these changes provides a potential link between insulin resistance and endothelial dysfunction, the early stage in the atherosclerotic process, in obese individuals, and in type 2 diabetic patients. Reduction of adipose tissue mass through weight reduction in association with exercise reduces TNF-α, IL-6, and PAI-1, increases adiponectin, and is associated with improved insulin sensitivity and endothelial function.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2000, 288:1723–1727.CrossRefGoogle Scholar
  2. 2.
    Balkau B, Eschwege E, Papoz L, et al.: Risk factors for early death in non-insulin dependent diabetes and men with known glucose intolerance status. BMJ 1993, 307:295–299.PubMedGoogle Scholar
  3. 3.
    Bergman RN, Mittelman SD: Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998, 9:205–221.PubMedGoogle Scholar
  4. 4.
    Saltiel AR: You are what you secrete. Nat Med 2001, 7:887–888.PubMedCrossRefGoogle Scholar
  5. 5.
    Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001, 60:349–356.PubMedGoogle Scholar
  6. 6.
    Mohamed-Ali V, Goodrick S, Bulmer K, et al.: Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999, 277(6 Pt 1):E971-E975.PubMedGoogle Scholar
  7. 7.
    Hotamisligil GS, Arner P, Caro JF, et al.: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409–2415.PubMedGoogle Scholar
  8. 8.
    Arner P: Regional differences in protein production by human adipose tissue. Biochem Soc Trans 2001, 29(Pt 2):72–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Mohamed-Ali V, Goodrick S, Rawesh A, et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196–4200.PubMedCrossRefGoogle Scholar
  10. 10.
    Scherer PE, Williams S, Fogliano M, et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746–26749.PubMedCrossRefGoogle Scholar
  11. 11.
    Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286–289.PubMedCrossRefGoogle Scholar
  12. 12.
    Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.PubMedCrossRefGoogle Scholar
  13. 13.
    Friedman J: Fat in all the wrong places. Nature 2002, 415:268–269.PubMedCrossRefGoogle Scholar
  14. 14.
    Dua A, Hennes MI, Hoffmann RG, et al.: Leptin: a significant indicator of total body fat but not of visceral fat and insulin insensitivity in African-American women. Diabetes 1996, 45:1635–1637.PubMedCrossRefGoogle Scholar
  15. 15.
    Shimomura I, Funahashi T, Takahashi M, et al.: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800–803.PubMedCrossRefGoogle Scholar
  16. 16.
    Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  17. 17.
    Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673–1677.PubMedCrossRefGoogle Scholar
  18. 18.
    Ventre J, Doebber T, Wu M, et al.: Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997, 46:1526–1531.PubMedCrossRefGoogle Scholar
  19. 19.
    Katsuki A, Sumida Y, Murashima S, et al.: Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83:859–862.PubMedCrossRefGoogle Scholar
  20. 20.
    Katsuki A, Sumida Y, Murata K, et al.: Troglitazone reduces plasma levels of tumor necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2000, 2:189–191.PubMedCrossRefGoogle Scholar
  21. 21.
    Stephens JM, Pekala PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991, 266:21839–21845.PubMedGoogle Scholar
  22. 22.
    Hotamisligil GS, Peraldi P, Budavari A, et al.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFalpha-and obesity-induced insulin resistance. Science 1996, 271:665–668.PubMedCrossRefGoogle Scholar
  23. 23.
    Strassmann G, Fong M, Windsor S, Neta R: The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993, 5:285–290.PubMedCrossRefGoogle Scholar
  24. 24.
    Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334.PubMedCrossRefGoogle Scholar
  25. 25.
    Bastard JP, Jardel C, Bruckert E, et al.: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000, 85:3338–342.PubMedCrossRefGoogle Scholar
  26. 26.
    Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731–737.PubMedCrossRefGoogle Scholar
  27. 27.
    Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941–946.PubMedCrossRefGoogle Scholar
  28. 28.
    Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ: Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998, 47:290–293.PubMedCrossRefGoogle Scholar
  29. 29.
    McGill JB, Schneider DJ, Arfken CL, et al.: Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994, 43:104–109.PubMedCrossRefGoogle Scholar
  30. 30.
    Havel PJ, Kasim-Karakas S, Mueller W, et al.: Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996, 81:406–413.CrossRefGoogle Scholar
  31. 31.
    Hube F, Hauner H: The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999, 31:626–631.PubMedCrossRefGoogle Scholar
  32. 32.
    Ehtisham NZ: Do resistin resist insulin? Curr Sci 2002, 83:1190–1191.Google Scholar
  33. 33.
    Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001, 285:561–564.PubMedCrossRefGoogle Scholar
  34. 34.
    Tooke JE, Hannemann MM: Adverse endothelial function and the insulin resistance syndrome. J Intern Med 2000, 247:425–431.PubMedCrossRefGoogle Scholar
  35. 35.
    Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endotheliumdependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432–438.PubMedGoogle Scholar
  36. 36.
    Gearing AJH, Hemingway J, Pigott R, et al.: Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1. Pathological significance. Ann N Y Acad Sci 1992, 667:324–331.PubMedCrossRefGoogle Scholar
  37. 37.
    Campbell JH, Campbell GR: Cell biology of atherosclerosis. J Hypertension 1994, 12:S129-S132.Google Scholar
  38. 38.
    Morise T, Takeuchi Y, Kawano M, et al.: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995, 18:87–89.PubMedCrossRefGoogle Scholar
  39. 39.
    Jovinge S, Hamsten A, Tornvall P, Proudler A: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47:113–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Zeng M, Zhang H, Lowell C, He P: Tumor necrosis factor-alphainduced leukocyte adhesion and microvessel permeability. Am J Physiol Heart Circ Physiol 2002, 283:H2420-H2430.PubMedGoogle Scholar
  41. 41.
    Ridker PM, Rifai N, Pfeffer M, et al.: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149–2153. This study links inflammation to the increased risk for recurrent myocardial infarction. It attracts the attention to the importance of inflammation in the atherosclerotic process.PubMedGoogle Scholar
  42. 42.
    Ziccardi P, Nappo F, Giugliano G, et al.: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804–809. The correlation between ED and obesity is clarified. It shows that weight reduction is associated with downregulation of the inflammatory state.PubMedCrossRefGoogle Scholar
  43. 43.
    Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184–2187.PubMedCrossRefGoogle Scholar
  44. 44.
    Kirchgessner TG, Uysal KT, Wiesbrock SM, et al.: Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997, 100:2777–2782.PubMedCrossRefGoogle Scholar
  45. 45.
    Ashton AW, Ware GM, Kaul DK, Ware JA: Inhibition of tumor necrosis factor alpha-mediated NFkappa B activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem 2003, 278:11858–11866.PubMedCrossRefGoogle Scholar
  46. 46.
    Patel JN, Jager A, Schalkwijk C, et al.: Effects of tumor necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci 2002, 103:409–415.PubMedGoogle Scholar
  47. 47.
    Weber C, Negrescu E, Erl W, Pietsch A: Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. Immunology 1995, 155:445–451.Google Scholar
  48. 48.
    Uzui H, Harpf A, Liu M, et al.: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002, 106:3024–3030.PubMedCrossRefGoogle Scholar
  49. 49.
    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767–1772.PubMedGoogle Scholar
  50. 50.
    Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972–978.PubMedGoogle Scholar
  51. 51.
    Romano M, Sironi M, Toniatti C, et al.: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte. Immunity 1997, 6:315–325.PubMedCrossRefGoogle Scholar
  52. 52.
    Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265:621–636.PubMedGoogle Scholar
  53. 53.
    Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002, 252:283–294.PubMedCrossRefGoogle Scholar
  54. 54.
    Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487–37491.PubMedCrossRefGoogle Scholar
  55. 55.
    Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.PubMedGoogle Scholar
  56. 56.
    Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767–2770.PubMedCrossRefGoogle Scholar
  57. 57.
    Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36–52.PubMedCrossRefGoogle Scholar
  58. 58.
    Minamikawa J, Yamauchi M, Inoue D, Koshiyama H: Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83:1041–1042.PubMedCrossRefGoogle Scholar
  59. 59.
    Bilsborough W, O'Driscoll G, Stanton K, et al.: Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in type II diabetes. Clin Sci 2002, 103:163–169.PubMedCrossRefGoogle Scholar
  60. 60.
    Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057–1063.PubMedGoogle Scholar
  61. 61.
    Hamdy O, Moussa A, Ledbury S, et al.: Effects of weight loss and increased physical activity on insulin and glucose dynamics in obese subjects with insulin resistance syndrome. Diabetes 2002, 51(suppl 2):A60.Google Scholar
  62. 62.
    Gabriely I, Ma XH, Yang XM, et al.: Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002, 51:2951–2958. The metabolic and biological changes associated with removal of visceral fat are clearly stated in this study.PubMedCrossRefGoogle Scholar
  63. 63.
    Brazilia N, She L, Liu BQ, et al.: Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999, 48:94–98.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Waleed Aldhahi
    • 1
  • Osama Hamdy
    • 1
  1. 1.Joslin Diabetes CenterBostonUSA

Personalised recommendations